Predictive Oncology (POAI) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Predictive Oncology in August 2026.
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping Predictive Oncology's stock as it shows limited growth potential.
Financial Health
Predictive Oncology Inc is generating moderate revenue and profit margins, with a positive cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.